Maria Bromberg

Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors

Samuel A. Funt, Deaglan Joseph McHugh, Andrea Knežević et al. · The Oncologist · 2021 · 18 citations · Full text

Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).

Darren R. Feldman, James Hu, Sandy Srinivas et al. · Journal of Clinical Oncology · 2018 · 17 citations

Versus Bleomycin, Cancer Management, Pathology +20

Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs

Michael L. Cheng, Mark T.A. Donoghue, François Audenet et al. · JCO Precision Oncology · 2020 · 17 citations · Full text

Analytical Validation and Performance Characteristics of Molecular Serum Biomarkers, miR-371a-3p and miR-372-3p, for Male Germ Cell Tumors, in a Clinical Laboratory Setting

Fei Ye, Darren R. Feldman, Alisa Valentino et al. · Journal of Molecular Diagnostics · 2022 · 16 citations · Full text

Prognostic Biomarkers, Oncology, Analytical Validation +10

Real world outcomes of sequential ADC therapy in metastatic breast cancer: Patients treated with sacituzumab govitecan and trastuzumab deruxtecan.

Nicholas Mai, Emanuela Ferraro, Maria Bromberg et al. · Journal of Clinical Oncology · 2024 · 14 citations